Nurix Therapeutics (NASDAQ:NRIX) Sets New 1-Year High at $32.97

Nurix Therapeutics, Inc. (NASDAQ:NRIX)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $32.97 and last traded at $31.21, with a volume of 221600 shares traded. The stock had previously closed at $29.81.

Several research analysts have issued reports on the company. Stifel Nicolaus began coverage on Nurix Therapeutics in a report on Tuesday, August 18th. They set a “buy” rating and a $34.00 price objective on the stock. Needham & Company LLC began coverage on Nurix Therapeutics in a research note on Tuesday, August 18th. They issued a “buy” rating and a $35.00 price target on the stock. JPMorgan Chase & Co. began coverage on Nurix Therapeutics in a research note on Tuesday, August 18th. They issued an “overweight” rating and a $35.00 price target on the stock. Finally, Piper Sandler began coverage on Nurix Therapeutics in a research note on Tuesday, August 18th. They issued an “overweight” rating and a $40.00 price target on the stock.

About Nurix Therapeutics (NASDAQ:NRIX)

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications.

See Also: The mechanics of the bid-ask spread in trading

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.